First Patient Treated in Aastrom Adult Stem Cell Trial for Critical Limb Ischemia

ANN ARBOR, Mich., Jun 27, 2007 (PrimeNewswire via COMTEX News Network) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a regenerative medicine company, today announced that the first critical limb ischemia (CLI) patient was treated at the Malcom Randall Veterans Affairs (VA) Medical Center in Gainesville, FL. The Company is evaluating its Vascular Repair Cell (VRC) product in a U.S. Phase IIb clinical trial to treat patients suffering from CLI, the most severe form of peripheral arterial disease (PAD).

Source: Aastrom Biosciences